BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kawahara T, Kojima T, Kandori S, Kurobe M, Yoshino T, Kimura T, Nagumo Y, Ishituka R, Mitsuzuka K, Narita S, Kobayashi T, Matsui Y, Ogawa O, Sugimoto M, Miyazaki J, Nishiyama H. TP53 codon 72 polymorphism is associated with FGFR3 and RAS mutation in non-muscle-invasive bladder cancer. PLoS One. 2019;14:e0220173. [PMID: 31369573 DOI: 10.1371/journal.pone.0220173] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kurobe M. Editorial Comment from Dr Kurobe to Telomerase reverse transcriptase promoter mutation in tumorigenesis of bladder cancer: Evolutionary trajectory by algorithmic inference from cross-sectional data. Int J Urol 2021;28:777. [PMID: 33942390 DOI: 10.1111/iju.14594] [Reference Citation Analysis]
2 Liao Y, Tang H, Wang M, Wang K, Wang Y, Jiang N. The potential diagnosis role of TP53 mutation in advanced bladder cancer: A meta-analysis. J Clin Lab Anal 2021;35:e23765. [PMID: 33780049 DOI: 10.1002/jcla.23765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Lambrou GI, Vichos K, Koutsouris D, Zaravinos A. Identification of Co-Deregulated Genes in Urinary Bladder Cancer Using High-Throughput Methodologies. Applied Sciences 2021;11:1785. [DOI: 10.3390/app11041785] [Reference Citation Analysis]
4 Tripathi K, Goel A, Singhai A, Garg M. Mutational analysis of Ras hotspots in patients with urothelial carcinoma of the bladder. World J Clin Oncol 2020; 11(8): 614-628 [PMID: 32879848 DOI: 10.5306/wjco.v11.i8.614] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]